Featured Research

from universities, journals, and other organizations

Candidate Genes Found Which May Play A Role In Cancer Progressing From Non-Invasive To Invasive

Date:
March 25, 2002
Source:
Federation Of European Cancer Societies
Summary:
Scientists have made the first steps in identifying a group of genes which may be involved in the progression of breast cancer from non-invasive to invasive.

Scientists have made the first steps in identifying a group of genes which may be involved in the progression of breast cancer from non-invasive to invasive, the 3rd European Breast Cancer Conference in Barcelona heard today (Thursday, March 21).

Professor Craig Allred, Director of Breast Pathology at the Breast Center, Baylor College of Medicine, Houston, USA, used a technique called microarray to discover which genes might be involved in causing ductal carcinoma in situ (DCIS) to progress to invasive breast cancer (IBC). Microarray studies involve using a microchip bearing thousands of known single-stranded gene fragments on its surface and incubating it with RNA from tissue samples. By seeing which gene fragments the RNA is attracted to it is possible to tell which genes are active in the tissue samples.

Prof Allred said: “DCIS is very common and gives rise to most IBCs. We already know that DCIS contains many genetic defects that are responsible for its development in the first place, but we believe that there are many additional genetic defects that must occur in DCIS to cause it to progress to IBC. Identifying the important genes will be useful because finding defects in them could help doctors to predict the outcome for the patients and, more importantly, could give us targets at which we could aim treatments to prevent or suppress invasion.”

Analyses of the results from the microarray studies showed that there were at least 100 individual genes which had significantly different levels of activity in DCIS and IBC, and many of these genes are known already to involve processes and pathways which could make them reasonable candidates as invasion-related genes.

Prof Allred said: “I don’t know whether any of the genes are truly ‘invasion-related’, but many of them are involved in biological pathways that are likely to be important in invasion. For example, several integrin genes, which are involved in making cells stick together, appear to be switched off in invasive tumours compared to non-invasive tumours. It is reasonable to assume from this that defects in these genes might make cells less sticky, which is probably necessary to becoming invasive. There are probably many defects involving processes such as cell adhesion, cell motility and so on that are required to make a normal breast cell become a malignant invasive cell. I expect these defects are acquired individually and accumulate over many years”

He continued: “The microarray experiments are only the first step to identifying candidate genes which may be important in invasion. Now we have to carry out further studies to discover whether they really are important or not. This will involve looking more closely at the proteins encoded by the genes, using clinical follow-up to see whether the genetic defects seen in the tumours are related to the outcome for the patient so that we know whether they are prognostic, and then testing whether the genes are actually responsible for suppressing or promoting tumour invasion.

“A few other laboratories are looking at this problem using different technical approaches and even with this group effort we are at least a few years away from actually having something to translate directly to patient care. If we do find genes responsible for tumour invasion, and if we can develop treatments to correct or prevent defects in them, then we have the chance to prevent lethal invasive breast cancer.”


Story Source:

The above story is based on materials provided by Federation Of European Cancer Societies. Note: Materials may be edited for content and length.


Cite This Page:

Federation Of European Cancer Societies. "Candidate Genes Found Which May Play A Role In Cancer Progressing From Non-Invasive To Invasive." ScienceDaily. ScienceDaily, 25 March 2002. <www.sciencedaily.com/releases/2002/03/020325080715.htm>.
Federation Of European Cancer Societies. (2002, March 25). Candidate Genes Found Which May Play A Role In Cancer Progressing From Non-Invasive To Invasive. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2002/03/020325080715.htm
Federation Of European Cancer Societies. "Candidate Genes Found Which May Play A Role In Cancer Progressing From Non-Invasive To Invasive." ScienceDaily. www.sciencedaily.com/releases/2002/03/020325080715.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins